Overview

* West Pharmaceutical Services ( WST ) Q3 net sales up 7.7%, beating analyst expectations

* Adjusted EPS for Q3 beats consensus, reflecting strong operational performance

* Company raises full-year 2025 revenue and EPS guidance, citing ongoing momentum

Outlook

* West Pharmaceutical raises full-year 2025 revenue guidance to $3.060 bln-$3.070 bln

* Company increases full-year 2025 adjusted EPS guidance to $7.06-$7.11

* West Pharmaceutical introduces Q4 2025 revenue guidance of $790 mln-$800 mln

* Company sets Q4 2025 adjusted EPS guidance at $1.81-$1.86

Result Drivers

* HVP COMPONENTS GROWTH - Double-digit growth in HVP Components driven by GLP-1 products and increased HVP conversion

* CONTRACT MANUFACTURING - Growth in Contract Manufacturing driven by self-injection devices for obesity and diabetes

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 NET Beat $804.60 $787.92

SALES mln mln (11

Analysts

)

Q3 Beat $1.96 $1.68

ADJUSTED (12

EPS Analysts

)

Q3 EPS $1.92

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

* Wall Street's median 12-month price target for West Pharmaceutical Services Inc ( WST ) is $311.00, about 10.2% above its October 21 closing price of $279.39

* The stock recently traded at 38 times the next 12-month earnings vs. a P/E of 33 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)